Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olof Bengtsson

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
Diabetes Care|October 21, 2020
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering TherapyKieran F Docherty, Pardeep S Jhund, Olof Bengtsson, et al.
Circulation. Heart Failure|November 9, 2020
Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?Su E Yeoh, Pooja Dewan, Pardeep S Jhund, et al.
JACC. Heart Failure|June 15, 2023
Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection FractionJawad H Butt, Kieran F Docherty, Mikhail N Kosiborod, et al.
JACC. Heart Failure|February 4, 2022
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HFKieran F Docherty, Joanne Simpson, Pardeep S Jhund, et al.
JAMA Cardiology|July 28, 2021
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical TrialKieran F Docherty, Pardeep S Jhund, Brian Claggett, et al.
JACC. Heart Failure|July 13, 2020
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF TrialScott D Solomon, Pardeep S Jhund, Brian L Claggett, et al.
European Heart Journal|August 27, 2021
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HFJames P Curtain, Kieran F Docherty, Pardeep S Jhund, et al.
JAMA Cardiology|February 17, 2021
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection FractionDavid D Berg, Pardeep S Jhund, Kieran F Docherty, et al.
European Journal of Heart Failure|February 22, 2021
Effect of dapagliflozin on anaemia in DAPA-HFKieran F Docherty, James P Curtain, Inder S Anand, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
Diabetes Care|October 21, 2020
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering TherapyKieran F Docherty, Pardeep S Jhund, Olof Bengtsson, et al.
Circulation. Heart Failure|November 9, 2020
Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?Su E Yeoh, Pooja Dewan, Pardeep S Jhund, et al.
JACC. Heart Failure|June 15, 2023
Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection FractionJawad H Butt, Kieran F Docherty, Mikhail N Kosiborod, et al.
JACC. Heart Failure|February 4, 2022
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HFKieran F Docherty, Joanne Simpson, Pardeep S Jhund, et al.
JAMA Cardiology|July 28, 2021
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical TrialKieran F Docherty, Pardeep S Jhund, Brian Claggett, et al.
JACC. Heart Failure|July 13, 2020
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF TrialScott D Solomon, Pardeep S Jhund, Brian L Claggett, et al.
European Heart Journal|August 27, 2021
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HFJames P Curtain, Kieran F Docherty, Pardeep S Jhund, et al.
JAMA Cardiology|February 17, 2021
Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection FractionDavid D Berg, Pardeep S Jhund, Kieran F Docherty, et al.
European Journal of Heart Failure|February 22, 2021
Effect of dapagliflozin on anaemia in DAPA-HFKieran F Docherty, James P Curtain, Inder S Anand, et al.
Pageof 8